Advanced search
Publication Cover
Diabetes, Metabolic Syndrome and Obesity Volume 16, 2023 - Issue
Submit an article Journal homepage
263
Views
7
CrossRef citations to date
0
Altmetric
RAPID COMMUNICATION

The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients

Chun-Feng Huang1 Division of Family Medicine, En Chu Kong Hospital, New Taipei City, Taiwan, Republic of China;2 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, Republic of China;3 Department of Leisure Services Management, Chaoyang University of Technology, Taichung, Taiwan, Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6265-5155
ORCID Icon,
Tso-Yen Mao3 Department of Leisure Services Management, Chaoyang University of Technology, Taichung, Taiwan, Republic of ChinaCorrespondence[email protected]
&
Shinn-Jang Hwang1 Division of Family Medicine, En Chu Kong Hospital, New Taipei City, Taiwan, Republic of China;2 Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, Republic of ChinaCorrespondence[email protected]
Pages 31-36 | Received 15 Sep 2022, Accepted 22 Dec 2022, Published online: 11 Jan 2023

References

  • Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi:10.1038/nrendo.2017.151
  • Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. Br Med Bull. 2020;133(1):105–117. doi:10.1093/bmb/ldaa005
  • Wang J, You W, Jing Z, Wang R, Fu Z, Wang Y. Increased risk of vertebral fracture in patients with diabetes: a meta-analysis of cohort studies. Int Orthop. 2016;40(6):1299–1307. doi:10.1007/s00264-016-3146-y
  • Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015;36(2):194–213. doi:10.1210/er.2012-1042
  • Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC. Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis. Front Endocrinol. 2021;12:735824. doi:10.3389/fendo.2021.735824
  • Rosenberg J, Jacob J, Desai P, Park J, Donovan L, Kim JY. Incretin hormones: pathophysiological risk factors and potential targets for type 2 diabetes. J Obes Metab Syndr. 2021;30(3):233–247. doi:10.7570/jomes21053
  • Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004;53(3):654–662. doi:10.2337/diabetes.53.3.654
  • Gutzwiller JP, Drewe J, Göke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276(5):R1541–R1544. doi:10.1152/ajpregu.1999.276.5.R1541
  • Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742. doi:10.1038/nrendo.2012.140
  • Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 2011;11:12. doi:10.1186/1472-6793-11-12
  • Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized Phase III study. Diabetes Obes Metab. 2016;18(3):249–257. doi:10.1111/dom.12602
  • Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48(1):107–115. doi:10.1007/s12020-014-0361-4
  • Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta. 2005;1751(1):33–44. doi:10.1016/j.bbapap.2005.05.010
  • Dombrowski S, Kostev K, Jacob L. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. Osteoporos Int. 2017;28(8):2421–2428. doi:10.1007/s00198-017-4051-y
  • Yang J, Huang C, Wu S, et al. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. PLoS One. 2017;12(12):e0187537. doi:10.1371/journal.pone.0187537
  • Yamamoto M, Sugimoto T. Advanced glycation end products, diabetes, and bone strength. Curr Osteoporos Rep. 2016;14(6):320–326. doi:10.1007/s11914-016-0332-1
  • Iepsen EW, Lundgren JR, Hartmann B, et al. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab. 2015;100(8):2909–2917. doi:10.1210/jc.2015-1176
  • Shapses SA, Riedt CS. Bone, body weight, and weight reduction: what are the concerns? J Nutr. 2006;136(6):1453–1456. doi:10.1093/jn/136.6.1453
  • Barchetta I, Cimini FA, Bloise D, Cavallo MG. Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link? Acta Diabetol. 2016;53(5):839–844. doi:10.1007/s00592-016-0882-9
  • Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology. 2000;141(3):1228–1235. doi:10.1210/endo.141.3.7366

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.